Cyber Week Deal Nlg919, Ido Pathway Inhibitor (tbi4564) Slash 30% Off The Price [yqr19QXf]

NLG919 IDO Pathway Inhibitor

NLG919 (1402836-58-1) is a highly potent IDO pathway inhibitor, designed for research applications in oncology and immunology. This innovative compound boasts a remarkable Ki value of 7nM and EC50 of 75nM, making it an effective tool for studying the IDO pathway. NLG919 has been shown to synergize with chemo-radiation therapy, enhancing T cell-dependent complement deposition in glioblastoma models. Its exceptional purity, exceeding 98%, and convenient powder formulation make it a valuable asset in various experimental settings.

• Potent IDO pathway inhibitor
• High purity >98%
• Convenient powder formulation

Product Specifications

NLG919 is formulated as a powder, offering easy handling and precise dosing. Its molecular formula is C₁₈H₂₂N₂O, with a formula weight of 282.39. This compound is highly soluble in DMSO, up to 10 mg/ml, making it suitable for various experimental applications. With a storage temperature of -20°C, NLG919 maintains stability for at least one year, ensuring long-term usability.

• Molecular Formula: C₁₈H₂₂N₂O
• Formula Weight: 282.39
• Solubility: Soluble in DMSO (up to 10 mg/ml)

Applications and Benefits

NLG919 is a versatile research tool with numerous applications in the study of IDO pathway inhibition. In combination with chemo-radiation therapy, NLG919 has demonstrated its ability to enhance immune responses and improve tumor outcomes in glioblastoma models. Additionally, when used with paclitaxel in melanoma models, NLG919 promotes the activation of T cells, increases the secretion of cytokines, and reduces regulatory T cell populations. This multifaceted compound is ideal for researchers looking to delve into the complex interactions of the IDO pathway and its role in cancer and immunological disorders.

• Inhibits IDO pathway in glioblastoma models
• Promotes T cell activation and cytokine secretion
• Reduces regulatory T cell populations